Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Protein crystallization promotes type 2 immunity and is reversible by antibody treatment.

Persson EK, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier JM, Deswarte K, Verschueren KHG, Dansercoer A, Gras D, Chanez P, Bachert C, Gonçalves A, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides SN, Lambrecht BN.

Science. 2019 May 24;364(6442). pii: eaaw4295. doi: 10.1126/science.aaw4295.

PMID:
31123109
2.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
3.

Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.

Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Kamar-Al Majidi S, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ.

Exp Neurol. 2019 Jul;317:133-143. doi: 10.1016/j.expneurol.2019.03.001. Epub 2019 Mar 6.

4.

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells.

Liénart S, Merceron R, Vanderaa C, Lambert F, Colau D, Stockis J, van der Woning B, De Haard H, Saunders M, Coulie PG, Savvides SN, Lucas S.

Science. 2018 Nov 23;362(6417):952-956. doi: 10.1126/science.aau2909. Epub 2018 Oct 25.

PMID:
30361387
5.

CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.

Van Hout A, Klarenbeek A, Bobkov V, Doijen J, Arimont M, Zhao C, Heukers R, Rimkunas R, de Graaf C, Verrips T, van der Woning B, de Haard H, Rucker JB, Vermeire K, Handel T, Van Loy T, Smit MJ, Schols D.

Biochem Pharmacol. 2018 Dec;158:402-412. doi: 10.1016/j.bcp.2018.10.015. Epub 2018 Oct 17.

PMID:
30342024
6.

Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.

Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ.

Biochem Pharmacol. 2018 Dec;158:413-424. doi: 10.1016/j.bcp.2018.10.014. Epub 2018 Oct 17.

7.

Display Technologies for Generation of Ig Single Variable Domains.

Bobkov V, van der Woning B, de Haard H.

Methods Mol Biol. 2018;1827:129-144. doi: 10.1007/978-1-4939-8648-4_7.

PMID:
30196495
8.

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N.

J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24.

9.

A bispecific antibody strategy to target multiple type 2 cytokines in asthma.

Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, Blanchetot C, Lambrecht BN.

J Allergy Clin Immunol. 2018 Oct;142(4):1185-1193.e4. doi: 10.1016/j.jaci.2018.06.002. Epub 2018 Jun 8.

PMID:
29890236
10.

A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3.

Bednenko J, Harriman R, Mariën L, Nguyen HM, Agrawal A, Papoyan A, Bisharyan Y, Cardarelli J, Cassidy-Hanley D, Clark T, Pedersen D, Abdiche Y, Harriman W, van der Woning B, de Haard H, Collarini E, Wulff H, Colussi P.

MAbs. 2018 May/Jun;10(4):636-650. doi: 10.1080/19420862.2018.1445451. Epub 2018 Apr 2.

11.

Therapeutic bispecific antibody formats: a patent applications review (1994-2017).

Godar M, de Haard H, Blanchetot C, Rasser J.

Expert Opin Ther Pat. 2018 Mar;28(3):251-276. doi: 10.1080/13543776.2018.1428307. Epub 2018 Jan 25. Review.

PMID:
29366356
12.

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C, Lardon F, Smits E, Pauwels P.

Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26.

13.

Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.

Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G.

MAbs. 2018 Jan;10(1):34-45. doi: 10.1080/19420862.2017.1392425. Epub 2017 Nov 14. Review.

14.

Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex.

Desmyter A, Spinelli S, Boutton C, Saunders M, Blachetot C, de Haard H, Denecker G, Van Roy M, Cambillau C, Rommelaere H.

Front Immunol. 2017 Aug 21;8:884. doi: 10.3389/fimmu.2017.00884. eCollection 2017.

15.

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P, Landro JA, Barucci N, Zavadoski WJ, Sun Z, de Haard H, Toth IV, Peloso GM, Natarajan P, Cuchel M, Lund-Katz S, Phillips MC, Tall AR, Kathiresan S, DaSilva-Jardine P, Yates NA, Rader DJ.

Nat Med. 2017 Sep;23(9):1086-1094. doi: 10.1038/nm.4390. Epub 2017 Aug 21.

16.

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.

Beirnaert E, Desmyter A, Spinelli S, Lauwereys M, Aarden L, Dreier T, Loris R, Silence K, Pollet C, Cambillau C, de Haard H.

Front Immunol. 2017 Jul 31;8:867. doi: 10.3389/fimmu.2017.00867. eCollection 2017.

17.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A.

Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1.

18.

A new anti-mesothelin antibody targets selectively the membrane-associated form.

Asgarov K, Balland J, Tirole C, Bouard A, Mougey V, Ramos D, Barroso A, Zangiacomi V, Jary M, Kim S, Gonzalez-Pajuelo M, Royer B, de Haard H, Clark A, Wijdenes J, Borg C.

MAbs. 2017 Apr;9(3):567-577. doi: 10.1080/19420862.2017.1288770.

19.

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.

Godar M, Morello V, Sadi A, Hultberg A, De Jonge N, Basilico C, Hanssens V, Saunders M, Lambrecht BN, El Khattabi M, de Haard H, Michieli P, Blanchetot C.

Sci Rep. 2016 Aug 22;6:31621. doi: 10.1038/srep31621.

20.

DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops.

van der Woning B, De Boeck G, Blanchetot C, Bobkov V, Klarenbeek A, Saunders M, Waelbroeck M, Laeremans T, Steyaert J, Hultberg A, De Haard H.

MAbs. 2016 Aug-Sep;8(6):1126-35. doi: 10.1080/19420862.2016.1189050. Epub 2016 May 21.

21.

Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies.

Blanchetot C, De Jonge N, Desmyter A, Ongenae N, Hofman E, Klarenbeek A, Sadi A, Hultberg A, Kretz-Rommel A, Spinelli S, Loris R, Cambillau C, de Haard H.

J Biol Chem. 2016 Jun 24;291(26):13846-54. doi: 10.1074/jbc.M115.695528. Epub 2016 Apr 27.

22.

Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.

Klarenbeek A, Blanchetot C, Schragel G, Sadi AS, Ongenae N, Hemrika W, Wijdenes J, Spinelli S, Desmyter A, Cambillau C, Hultberg A, Kretz-Rommel A, Dreier T, De Haard HJ, Roovers RC.

Protein Eng Des Sel. 2016 Apr;29(4):123-33. doi: 10.1093/protein/gzw003. Epub 2016 Mar 5.

PMID:
26945588
23.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

24.

Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform.

Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, Roovers RC, Cambillau C, Spinelli S, Del-Favero J, Verrips T, de Haard HJ, Achour I.

MAbs. 2015;7(4):693-706. doi: 10.1080/19420862.2015.1046648.

25.

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Cuende J, Liénart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, Renauld JC, De Haard H, Saunders M, Coulie PG, Lucas S.

Sci Transl Med. 2015 Apr 22;7(284):284ra56. doi: 10.1126/scitranslmed.aaa1983.

26.

Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.

McCoy LE, Groppelli E, Blanchetot C, de Haard H, Verrips T, Rutten L, Weiss RA, Jolly C.

Retrovirology. 2014 Oct 2;11:83. doi: 10.1186/s12977-014-0083-y.

27.

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P.

J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27.

28.

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.

Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, Thibault A, De Haard HJ.

MAbs. 2014 Mar-Apr;6(2):523-32. doi: 10.4161/mabs.27398. Epub 2013 Dec 6.

29.

Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.

Blanchetot C, Verzijl D, Mujić-Delić A, Bosch L, Rem L, Leurs R, Verrips CT, Saunders M, de Haard H, Smit MJ.

J Biol Chem. 2013 Aug 30;288(35):25173-82. doi: 10.1074/jbc.M113.467969. Epub 2013 Jul 8.

30.

Selection of nanobodies that target human neonatal Fc receptor.

Andersen JT, Gonzalez-Pajuelo M, Foss S, Landsverk OJ, Pinto D, Szyroki A, de Haard HJ, Saunders M, Vanlandschoot P, Sandlie I.

Sci Rep. 2013;3:1118. doi: 10.1038/srep01118. Epub 2013 Jan 23.

31.

Improvement of proteolytic stability through in silico engineering.

Rutten L, de Haard H, Verrips T.

Methods Mol Biol. 2012;911:373-81. doi: 10.1007/978-1-61779-968-6_22.

PMID:
22886263
32.

Expression of VHHs in Saccharomyces cerevisiae.

Gorlani A, de Haard H, Verrips T.

Methods Mol Biol. 2012;911:277-86. doi: 10.1007/978-1-61779-968-6_17.

PMID:
22886258
33.

Selection of VHHs under application conditions.

Dolk E, Verrips T, de Haard H.

Methods Mol Biol. 2012;911:199-209. doi: 10.1007/978-1-61779-968-6_13.

PMID:
22886254
34.

Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.

Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T.

PLoS One. 2012;7(3):e33298. doi: 10.1371/journal.pone.0033298. Epub 2012 Mar 15.

35.

Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH.

Emmerson CD, van der Vlist EJ, Braam MR, Vanlandschoot P, Merchiers P, de Haard HJ, Verrips CT, van Bergen en Henegouwen PM, Dolk E.

PLoS One. 2011;6(10):e26299. doi: 10.1371/journal.pone.0026299. Epub 2011 Oct 14.

36.

Llama antibody fragments have good potential for application as HIV type 1 topical microbicides.

Gorlani A, Brouwers J, McConville C, van der Bijl P, Malcolm K, Augustijns P, Quigley AF, Weiss R, De Haard H, Verrips T.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):198-205. doi: 10.1089/aid.2011.0133. Epub 2011 Aug 24.

PMID:
21864083
37.

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ.

PLoS One. 2011 Apr 1;6(4):e17665. doi: 10.1371/journal.pone.0017665.

38.

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20565-70. doi: 10.1073/pnas.1012865107. Epub 2010 Nov 8.

39.

Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.

Hinz A, Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W.

PLoS One. 2010 May 5;5(5):e10482. doi: 10.1371/journal.pone.0010482.

40.

Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1.

Koh WW, Steffensen S, Gonzalez-Pajuelo M, Hoorelbeke B, Gorlani A, Szynol A, Forsman A, Aasa-Chapman MM, de Haard H, Verrips T, Weiss RA.

J Biol Chem. 2010 Jun 18;285(25):19116-24. doi: 10.1074/jbc.M110.116699. Epub 2010 Apr 16.

41.

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.

Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P.

Mucosal Immunol. 2010 Jan;3(1):49-56. doi: 10.1038/mi.2009.116. Epub 2009 Sep 30.

PMID:
19794409
42.

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.

Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, de Haard H, Weiss RA.

J Virol. 2008 Dec;82(24):12069-81. doi: 10.1128/JVI.01379-08. Epub 2008 Oct 8.

43.

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.

Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA.

Mol Cancer Ther. 2008 Aug;7(8):2288-97. doi: 10.1158/1535-7163.MCT-07-2384.

44.

Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope.

Deroo S, Fischer A, Beaupain N, Counson M, Boutonnet N, Pletinckx J, Loverix S, Beirnaert E, De Haard H, Schmit JC, Lasters I.

Mol Immunol. 2008 Mar;45(5):1366-73. Epub 2007 Oct 23.

PMID:
17936360
45.

Lactobacillli expressing llama VHH fragments neutralise Lactococcus phages.

Hultberg A, Tremblay DM, de Haard H, Verrips T, Moineau S, Hammarström L, Marcotte H.

BMC Biotechnol. 2007 Sep 17;7:58.

46.

Properties, production, and applications of camelid single-domain antibody fragments.

Harmsen MM, De Haard HJ.

Appl Microbiol Biotechnol. 2007 Nov;77(1):13-22. Epub 2007 Aug 18. Review.

47.

Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology.

Klooster R, Maassen BT, Stam JC, Hermans PW, Ten Haaft MR, Detmers FJ, de Haard HJ, Post JA, Theo Verrips C.

J Immunol Methods. 2007 Jul 31;324(1-2):1-12. Epub 2007 May 11.

PMID:
17570391
48.

Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation.

Verheesen P, Roussis A, de Haard HJ, Groot AJ, Stam JC, den Dunnen JT, Frants RR, Verkleij AJ, Theo Verrips C, van der Maarel SM.

Biochim Biophys Acta. 2006 Aug;1764(8):1307-19. Epub 2006 Jun 10.

PMID:
16872921
49.

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.

Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen en Henegouwen PM.

Cancer Immunol Immunother. 2007 Mar;56(3):303-317.

PMID:
16738850
50.

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.

Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P.

Arthritis Rheum. 2006 Jun;54(6):1856-66.

Supplemental Content

Loading ...
Support Center